The letter by Alderman and colleagues is a timely reminder of the continued importance of post-marketing surveillance, especially for medications with frequently encountered and well characterised harms. As outlined, such surveillance must include all medications, whether or not they are subsidised or sold over the counter, in order to account for drug–host and drug–drug interactions.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.